Dr. Feixiong Cheng is a postdoctoral research fellow in the Department of Biomedical Informatics in the Vanderbilt University Medical Center (United States). He developed new statistical, network-based algorithms, and integrative genomics framework to address the big data (e.g., next generation sequencing, electronic health records, etc) challenges for genome-wide pharmacogenetic and pharmacogenomic studies. His interests span areas of cancer genomics, network biology, systems pharmacology and biology, pharmacogenomics, translational bioinformatics, computational biology and chemistry, and many more. Dr. Cheng received his Ph.D. degree in medical chemistry (pharmacoinformatics and network pharmacology) from the East China University of Science and Technology at Shanghai (China) in 2013. He received his BS degree in pharmaceutics from Shanxi University of Science and Technology at Xian (China) in 2008. Dr. Cheng has over 7 years of bioinformatics, genomics, computational biology and chemistry research experience and has published over 30 peer-reviewed papers in these areas. He is considered an experienced scientist in the application of computational biology, bioinformatics, and integrative genetics and genomics analysis in cancer systems biology, pharmacogenomics, drug design, and P4 medicine (Predictive, preventive, Personalized, and Participatory). He developed several useful databases, tools, and algorithms, including NBI, CPI-predictor, ademtSAR, ADMET-Simulator, MetaADEDB, among others, for network biology, systems pharmacology, translational bioinformatics studies. These algorithms, databases and tools have been widely used by more than 80 academic and industrial research groups from the USA (Harvard University, University of Minnesota etc.), as well as other countries, including but not limited to Canada, England (Novartis, University of Cambridge), Germany, Denmark, India, Brazil, South Korea, and China. For example, the admetSAR has been installed in two famous databases, DrugBank and ChEMBL, which widely used to predict the PK/PD or toxicity of small molecules in early stage drug development. In addition, one paper published in PLoS Comput Biol in 2012 has been downloaded over 15,000 times by readers and cited 70 times. Several famous review journals, such as Trends Pharmacology Science, and Drug Discovery Today reviewed and highlighted this work. Dr. Cheng has served as an invited reviewer for several interactional journals, including Bioinformatics, Molecular Biosystems, PLoS One, BMC Bioinformatics, BioMed Research International, Computational and Structural Biotechnology Journal, Journal of Bioinformatics and Computational Biology, and others. He has served as a keynote speaker or oral presenter in over 10 international and national conferences. Dr. Cheng has received several awards, including 2012 National Fellowships of PhD Graduate Students, Excellent Oral Report Award in Medicinal Chemistry in 2012, Shanghai Outstanding Graduates in 2013, Cheng Siwei?s Honorary Chancellor Scholarship in 2012, and others.